FY2025 · ended Dec 31, 2025 · Revenue $13.95B, +7.2% YoY · Filed Feb 24, 2026
Labcorp Holdings Inc. (LH) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14.0 billion and net income of $876.5 million. Free cash flow was $1.2 billion. As of Sep 30, 2026 it held $261.8 million in cash and investments and $6.8 billion in total debt.
Revenue (TTM)
$14.59B
+6.0% vs year-ago TTM
Net income (TTM)
$1.00B
+17.4% vs year-ago TTM
Operating cash flow (TTM)
$1.81B
+0.6% vs year-ago TTM
Free cash flow (TTM)
$1.29B
-6.8% vs year-ago TTM
EPS (TTM)
$12.19
+19.7% vs year-ago TTM
Dividend per share (TTM)
$2.88
Shares outstanding
82.40M
-1.6% vs prior year
Net cash
$-6.51B
as of Sep 30, 2026
Operating margin
10.3%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- LH (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Burlington, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 920148
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS (until May 16, 2024); NATIONAL HEALTH LABORATORIES HOLDINGS INC (until Feb 13, 1995)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2021 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.0B | $13.0B | $12.2B | $11.9B | $13.1B |
| Operating income | $1.4B | $1.1B | $725.6M | $1.4B | $3.0B |
| Net income | $876.5M | $746.0M | $418.0M | $1.3B | $2.4B |
| Diluted EPS | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 |
| Operating cash flow | $1.6B | $1.6B | $1.3B | $2.0B | $3.1B |
| Free cash flow | $1.2B | $1.1B | $874.1M | $1.5B | $2.7B |
| Total assets | $18.4B | $18.4B | $16.7B | $20.2B | $20.4B |
| Total liabilities | $9.8B | $10.3B | $8.8B | $10.0B | $10.1B |
| Stockholders' equity | $8.6B | $8.1B | $7.9B | $10.1B | $10.3B |
| Cash and investments | $532.3M | $1.5B | $536.8M | $320.6M | $1.5B |
| Total debt | $6.5B | $6.3B | $5.0B | $5.9B | $6.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
All 1002 Labcorp Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.